Therapy prediction and optimization for renal failure blood therapy

A renal failure blood therapy system comprising:

• a renal failure blood therapy machine configured to administer a renal failure blood treatment to a patient according to a therapy prescription;
• and
• a computing device communicatively coupled to the renal failure blood therapy machine and configured to
• receive a therapy target for the patient, the therapy target including at least one of (i) a target removal of ultrafiltration (“UF”), (ii) a target removal of beta 2-microglobulin (“β2-M”), (iii) a target removal of phosphate, or (iv) a target removal of urea,
• receive a desired solute concentration for the patient,
• apply the therapy target and the desired solute concentration as inputs to an optimization routine, the optimization routine being configured to use the therapy target and the desired solute concentration as the inputs for at least one kinetic modeling equation,
• execute the optimization routine to determine at least one dialysis therapy prescription specifying at least a dialysis therapy duration, a dialysis therapy frequency, and at least one of a dialysis therapy blood flow rate (“QB”) or a dialysis therapy dialysate flow rate (“QD”),
• display the at least one dialysis therapy prescription for confirmation or selection by a clinician, and
• transmit the selected or confirmed dialysis therapy prescription to the renal failure blood therapy machine to cause the renal failure blood therapy machine to use the selected or confirmed dialysis therapy prescription for the patient,
• wherein the at least one kinetic modeling equation includes:
• KIC, which is the patient's inter-compartmental diffusion coefficient for a molecule or a solute,
• KD, which is a known dialyzer clearance for a molecule or solute,
• KM, which is the patient's phosphorus mobilization clearance,
• KNR, which is the patient's residual kidney coefficient for a molecule or solute,
• V is a distribution volume of phosphorus,
• G, which is a generation rate for a solute or molecule produced by a patient's intake,
• VP, which is a perfused or extracellular volume, and
• VD, which is a solute distribution volume in a body, equal to VP+VNP for urea and beta2-microglubin.